Emerging data on oral selective estrogen receptor degraders

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating oral selective estrogen receptor degraders, including trials exploring use of elacestrant in combination with other therapies.

EP: 1.Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC

EP: 2.Episode 2: Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1 mutations with other alterations

EP: 4.Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease

EP: 5.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

EP: 6.Elacestrant: Clinical Pearls for Adverse Effect Management

Now Viewing

EP: 7.Emerging data on oral selective estrogen receptor degraders

Recent Videos